Beam Therapeutics Inc
NASDAQ:BEAM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.22
45.07
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Beam Therapeutics Inc
Beam Therapeutics Inc
Total Current Liabilities
Beam Therapeutics Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
Total Current Liabilities
$205.6m
|
CAGR 3-Years
26%
|
CAGR 5-Years
52%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
20%
|
CAGR 10-Years
21%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$20.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$4B
|
CAGR 3-Years
28%
|
CAGR 5-Years
23%
|
CAGR 10-Years
27%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
24%
|
|
Beam Therapeutics Inc
Glance View
Beam Therapeutics Inc. stands at the cutting edge of the biotechnology sector, pioneering the fascinating realm of gene editing through its unique approach known as base editing. Conceived from the intellectual explorations of world-renowned scientists, Beam Therapeutics intertwines science and innovation to redesign the genetic fabric that defines life. Unlike traditional gene-editing techniques that involve breaking the DNA strands, Beam’s base editing is precise and subtle, modifying individual letters of the genetic code without introducing double-stranded breaks. This precision technology has significant implications, offering potential treatments for a spectrum of genetic disorders that have long eluded medical science. The company’s business model is intricately linked to the commercialization of its novel base editing platforms and the development of therapeutic candidates targeting critical genetic diseases. By strategically partnering with pharmaceutical giants, Beam Therapeutics leverages its cutting-edge technology to stimulate revenue streams through collaborations and licensing agreements. Additionally, the company aims to navigate the complex pathways of regulatory approval, advancing its drug candidates from laboratory research through clinical trials towards eventual market rollouts. As such, Beam Therapeutics is not merely focused on scientific discovery but is equally committed to transforming these breakthroughs into viable products that can, one day, redefine the clinical landscape of genetic medicine.
See Also
What is Beam Therapeutics Inc's Total Current Liabilities?
Total Current Liabilities
205.6m
USD
Based on the financial report for Dec 31, 2023, Beam Therapeutics Inc's Total Current Liabilities amounts to 205.6m USD.
What is Beam Therapeutics Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
52%
Over the last year, the Total Current Liabilities growth was -8%. The average annual Total Current Liabilities growth rates for Beam Therapeutics Inc have been 26% over the past three years , 52% over the past five years .
You don't have any saved screeners yet
